# A Study of the Efficacy and Safety of PXL770 Versus Placebo After 12 Weeks of Treatment in Patients With NAFLD

> **NCT03763877** · PHASE2 · COMPLETED · sponsor: **Poxel SA** · enrollment: 121 (actual)

## Conditions studied

- Nonalcoholic Fatty Liver

## Interventions

- **DRUG:** PXL770
- **DRUG:** Placebo Oral Capsule

## Key facts

- **NCT ID:** NCT03763877
- **Lead sponsor:** Poxel SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-29
- **Primary completion:** 2020-08-03
- **Final completion:** 2020-08-10
- **Target enrollment:** 121 (ACTUAL)
- **Last updated:** 2021-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03763877

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03763877, "A Study of the Efficacy and Safety of PXL770 Versus Placebo After 12 Weeks of Treatment in Patients With NAFLD". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03763877. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*